| Type 2 Diabetes Mellitus |
1 |
1 |
| Chronic Kidney Disease |
0 |
0.98 |
| Renal Failure |
0 |
0.98 |
| Renal Disease |
0 |
0.82 |
| Kidney |
0 |
0.62 |
| Heart Failure (HF) |
0 |
0.4 |
| Risk Management |
0 |
0.31 |
| SGLT2 Inhibitor |
0 |
0.99 |
| Cardiovascular Imaging |
0 |
0.29 |
| Heart |
0 |
0.27 |
| Hypertension |
0 |
0.27 |
| Cardiovascular Risk Management |
0 |
0.25 |
| Ejection Fraction |
0 |
0.13 |
| Angiotensin II Receptor Blockade |
0 |
0.09 |
| Cardiovascular disease |
0 |
0.09 |
| Clinical Research |
0 |
0.09 |
| Diabetes Mellitus |
0 |
0.09 |
| Receptors |
0 |
0.09 |
| Healthcare and Medical Technology |
0 |
0.08 |
| Lipids Management |
0 |
0.08 |
| ACE Inhibitor |
0 |
0.04 |
| Biomarker |
0 |
0.04 |
| Epidemiology |
0 |
0.04 |
| Muscle |
0 |
0.04 |
| Professional Practice |
0 |
0.04 |
| Revenue and Practice Management |
0 |
0.04 |
| Statins |
0 |
0.04 |
| Triglycerides |
0 |
0.04 |